Hyderabad is a home to 800 pharma companies and life sciences capital of the country. To make the state free of spurious drugs, the Drugs Control Administration (DCA), Telangana is working relentlessly to detect spurious drugs movement in the market. In 2023 the DCA has carried out 26,133 inspections and taken action in 4984 cases with 4991 cases of violations. In the first four months of this year till April 2024 DCA has carried out 8495 inspections and found out that 50 drugs are ‘Not of Standard Quality’ (NSQ). Let’s look at how DCA is continuing its crusade against the spurious drugs issue and keep the public health of the state in order.
From the beginning of 2024, the DCA of Telangana, under the leadership of Director General (DG) V B Kamalasan Reddy, (who took charge as DG in July 2023) has intensified its efforts to combat the menace of spurious, fake and NSQ in the state. In the past few months, the DCA has targeted nearly 100 facilities across the state, resulting in the confiscation of 4000 to 5000 kgs of counterfeit medications worth Rs 50-60 crore. These recent raids have uncovered a widespread network of spurious drugs, highlighting the ongoing battle against counterfeit medications that pose a severe threat to public health.
Highlighting the efforts taken by the DCA of Telangana, Kamalasan Reddy said that he is committed to ensuring that quality, efficacy, and safety of medicines being supplied to the people in the state. “As part of this objective, we at the DCA have set our goals and accordingly devised plans for inspecting pharmaceutical companies, medical shops, medical device manufacturing companies, and blood banks across the state,” said Kamalasan Reddy.
Emerging pharmaceutical hub
This story is from the BioSpectrum India Oct 2024 edition of Bio Spectrum.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the BioSpectrum India Oct 2024 edition of Bio Spectrum.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Agilent releases nextgen HPLC systems with enhanced automation and sustainability capabilities
Agilent Technologies Inc. has announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems, all including the biocompatible versions.
Univercells Technologies launches miniaturised scale-X Nexo Bioreactor
Univercells Technologies has announced the launch of its latest innovation, the scale-X nexo bioreactor.
Thermo Fisher and Telangana to establish Bioprocess Design Centre for novel biotherapeutics
Thermo Fisher Scientific has announced the signing of a Memorandum of Understanding (MoU) with the Government of Telangana to establish a Bioprocess Design Centre (BDC) in Genome Valley, Hyderabad.
VFL Sciences announces launch of GreatFlo Parallel Bioreactors and Fermentors
Chennai-based VFL Sciences has announced the launch of GreatFlo Parallel, a range of seamlessly parallel Bioreactors and Fermentors at the IKMC 2024 event organised by IKP Knowledge Park at Hyderabad recently, by Dr Jitendra Kumar, Managing Director, BIRAC.
Avantor opens new innovation centre for solving life science's biggest challenges
Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, has announced the opening of its new flagship Bridgewater Innovation Centre.
Waters unveils new software to deliver lab-centric business intelligence
Waters Corporation has announced the launch of waters connect Data Intelligence software, a new cloud-based application that helps customers in regulated industries improve how they access, organise, analyse, and drive productivity from laboratory information.
INST develops unique drug delivery method to improve treatment of brain TB
Researchers at the Institute of Nano Science and Technology (INST), Mohali, have created a unique way to deliver Tuberculosis (TB) medicines directly to the brain bypassing the challenging blood-brain barrier (BBB) that limits the effectiveness of many brain TB medicines.
New way to create hydrogels from viral protein fragments for improving drug delivery
Researchers from Bose Institute, an autonomous institute of the Department of Science and Technology (DST), in Kolkata, have discovered a new way to create hydrogels using tiny protein fragments of just five amino acids from the SARS-CoV-1 virus, that could help improve targeted drug delivery & reduce side effects.
Lupin appoints Claus Jepsen as President, Global Specialty
Global pharma major Lupin has announced the appointment of Claus Jepsen as President, Global Specialty.
Shyamakant Giri to join as CEO of Gland Pharma
Gland Pharma’s Board has approved the appointment of Shyamakant Giri, as the new Chief Executive Officer (CEO) of the company.